期刊
VACCINE
卷 28, 期 41, 页码 6684-6691出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.08.007
关键词
Bifidobacterium; Mucosal vaccine; Salmonella
资金
- Japan Society for the Promotion of Science (JSPS) [20591201]
- Hyogo Science and Technology Association
- Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan
- KICOS [K20704000007-09A0500-00710]
- Grants-in-Aid for Scientific Research [20591201] Funding Source: KAKEN
We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5 x 10(7) CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0 x 10(7) CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据